BRIEF—Teva launches generic of big-selling angina drug
29 May 2019
Israeli generics company Teva Pharmaceutical Industries has launched a copy of Ranexa (ranolazine) in the USA.
The chronic angina drug has had sales of nearly $938 million in the USA over the past year, according to IQVIA data.
The reference product is marketed by US biotech Gilead Sciences, which has set its 2019 guidance in anticipation of the entry of a generic version of Ranexa.
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze